BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20920321)

  • 1. Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis.
    Illnait-Zaragozí MT; Martínez-Machín GF; Fernández-Andreu CM; Hagen F; Boekhout T; Klaassen CH; Meis JF
    BMC Infect Dis; 2010 Oct; 10():289. PubMed ID: 20920321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.
    Bertout S; Drakulovski P; Kouanfack C; Krasteva D; Ngouana T; Dunyach-Rémy C; Dongtsa J; Aghokeng A; Delaporte E; Koulla-Shiro S; Reynes J; Mallié M
    Clin Microbiol Infect; 2013 Aug; 19(8):763-9. PubMed ID: 23033854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptococcus neoformans isolates from Yaoundé human immunodeficiency virus-infected patients exhibited intra-individual genetic diversity and variation in antifungal susceptibility profiles between isolates from the same patient.
    Kammalac Ngouana T; Drakulovski P; Krasteva D; Kouanfack C; Reynes J; Delaporte E; Boyom FF; Mallié M; Bertout S
    J Med Microbiol; 2016 Jul; 65(7):579-589. PubMed ID: 27100672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic diversity in clinical and environmental isolates of Cryptococcus neoformans from India using multilocus microsatellite and multilocus sequence typing.
    Prakash A; Sundar G; Sharma B; Hagen F; Meis JF; Chowdhary A
    Mycoses; 2020 Mar; 63(3):284-293. PubMed ID: 31820495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
    Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
    Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microevolution of Serial Clinical Isolates of
    Chen Y; Farrer RA; Giamberardino C; Sakthikumar S; Jones A; Yang T; Tenor JL; Wagih O; Van Wyk M; Govender NP; Mitchell TG; Litvintseva AP; Cuomo CA; Perfect JR
    mBio; 2017 Mar; 8(2):. PubMed ID: 28270580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China.
    Fan X; Xiao M; Chen S; Kong F; Dou HT; Wang H; Xiao YL; Kang M; Sun ZY; Hu ZD; Wan Z; Chen SL; Liao K; Chu YZ; Hu TS; Zou GL; Hou X; Zhang L; Zhao YP; Xu YC; Liu ZY
    Clin Microbiol Infect; 2016 Oct; 22(10):887.e1-887.e9. PubMed ID: 27432767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
    Bii CC; Makimura K; Abe S; Taguchi H; Mugasia OM; Revathi G; Wamae NC; Kamiya S
    Mycoses; 2007 Jan; 50(1):25-30. PubMed ID: 17302744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.
    Arsic Arsenijevic V; Pekmezovic MG; Meis JF; Hagen F
    Mycoses; 2014 Jun; 57(6):380-7. PubMed ID: 24438323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsatellite typing of clinical and environmental Cryptococcus neoformans var. grubii isolates from Cuba shows multiple genetic lineages.
    Illnait-Zaragozi MT; Martínez-Machín GF; Fernández-Andreu CM; Boekhout T; Meis JF; Klaassen CH
    PLoS One; 2010 Feb; 5(2):e9124. PubMed ID: 20161737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.
    Matos CS; de Souza Andrade A; Oliveira NS; Barros TF
    Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1647-52. PubMed ID: 22278291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Most cases of cryptococcal meningitis in HIV-uninfected patients in Vietnam are due to a distinct amplified fragment length polymorphism-defined cluster of Cryptococcus neoformans var. grubii VN1.
    Day JN; Hoang TN; Duong AV; Hong CT; Diep PT; Campbell JI; Sieu TP; Hien TT; Bui T; Boni MF; Lalloo DG; Carter D; Baker S; Farrar JJ
    J Clin Microbiol; 2011 Feb; 49(2):658-64. PubMed ID: 21159929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian city, Rio de Janeiro.
    Igreja RP; Lazéra Mdos S; Wanke B; Galhardo MC; Kidd SE; Meyer W
    Med Mycol; 2004 Jun; 42(3):229-38. PubMed ID: 15283237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
    Illnait-Zaragozi MT; Martínez GF; Curfs-Breuker I; Fernández CM; Boekhout T; Meis JF
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1580-2. PubMed ID: 18212095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil.
    Almeida AM; Matsumoto MT; Baeza LC; de Oliveira E Silva RB; Kleiner AA; Melhem Mde S; Mendes Giannini MJ;
    FEMS Yeast Res; 2007 Jan; 7(1):152-64. PubMed ID: 17311593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.